Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 20/20 | 0.84 |
| ▸ | RXRA | P19793 | 18/20 | 0.84 |
| ▸ | NR1H3 | Q13133 | 18/20 | 0.84 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL779541 | 0.91 | NR1H2 (1.00) | NR1H2RXRANR1H3NR1I2 | |
| SCHEMBL20235389 | 0.91 | NR1H2 (0.89) | NR1H2RXRANR1H3NR1I2 | |
| Bms-852927 SCHEMBL779963 | 0.87 | NR1H2 (1.00) | NR1H2RXRANR1H3NR1I2 | |
| SCHEMBL780318 | 0.87 | NR1H2 (0.86) | NR1H2RXRANR1H3NR1I2 | |
| SCHEMBL780880 | 0.86 | NR1H2 (1.00) | NR1H2RXRANR1H3NR1I2 | |
| SCHEMBL788358 | 0.86 | NR1H2 (0.84) | NR1H2RXRANR1H3NR1I2 | |
| SCHEMBL16407947 | 0.85 | NR1H2 (0.89) | NR1H2RXRANR1H3NR1I2 | |
| SCHEMBL20230565 | 0.85 | NR1H2 (0.79) | NR1H2RXRANR1H3NR1I2 | |
| SCHEMBL778357 | 0.84 | NR1H2 (0.65) | NR1H2RXRANR1H3NR1I2 | |
| SCHEMBL779280 | 0.83 | NR1H2 (1.00) | NR1H2RXRANR1H3NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10543183-B2 | Treatment and diagnosis of melanoma | THE ROCKEFELLER UNIVERSITY (US) | 2020-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10543183-B2 | Treatment and diagnosis of melanoma | EYA3, BRAF, CD99 | NR1H2 4537/4885RXRA 2268/4885NR1H3 4400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.